Evidence map›Paper›PMID 30324419›Full record

ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2018

Mitochondrial pathophysiology beyond the retinal ganglion cell: occipital GABA is decreased in autosomal dominant optic neuropathy.

Otília C d'Almeida, Inês R Violante, Bruno Quendera, Miguel Castelo-Branco

Open access · hybridAbstract read
In one paragraph

Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Red Flags in Primary Mitochondrial Diseases: What Should We Recognize?International journal of molecular sciences · 2023
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Otília C d'AlmeidaVisual Neuroscience Laboratory, Institute for Biomedical Imaging and Life Sciences (CNC.IBILI), Faculty of Medicine, University of Coimbra, Azinhaga de Santa Comba, 3000-548, Coimbra, Portugal.
Inês R ViolanteSchool of Psychology, Faculty of Health and Medical Sciences, University of Surrey, Guildford, UK.
Bruno QuenderaVisual Neuroscience Laboratory, Institute for Biomedical Imaging and Life Sciences (CNC.IBILI), Faculty of Medicine, University of Coimbra, Azinhaga de Santa Comba, 3000-548, Coimbra, Portugal.
Miguel Castelo-BrancoVisual Neuroscience Laboratory, Institute for Biomedical Imaging and Life Sciences (CNC.IBILI), Faculty of Medicine, University of Coimbra, Azinhaga de Santa Comba, 3000-548, Coimbra, Portugal. mcbranco@fmed.uc.pt.ORCID http://orcid.org/0000-0003-4364-6373
University of Coimbra · PTUniversity of Surrey · GB

Funding

Centro 2020 FEDER CENTRO-01-0145-FEDER-000016European Regional Development Fund BIGDATIMAGEFundação para a Ciência e a Tecnologia COMPETE POCI-01-0145-FEDER-007440Fundação para a Ciência e a Tecnologia FCT-UID/4539/2013 - COMPETEFundação para a Ciência e a Tecnologia PAC-MEDPERSYSTFundação para a Ciência e a Tecnologia POCI-01-0145-FEDER-016428Fundação para a Ciência e a Tecnologia SFRH/BD/76013/2011
6 · The paper itself

Abstract

purposeIt has remained a mystery why some genetic mitochondrial disorders affect predominantly specific cell types such as the retinal ganglion cell. This is particularly intriguing concerning retinal and cortical function since they are tightly linked in health and disease. Autosomal dominant optic neuropathy (ADOA) is a mitochondrial disease that affects the ganglion cell. However, it is unknown whether alterations are also present in the visual cortex, namely in excitation/inhibition balance.

methodsIn this study, we performed in vivo structural and biochemical proton magnetic resonance imaging in 14 ADOA and 11 age-matched control participants focusing on the visual cortex, with the aim of establishing whether in this genetically determined disease an independent cortical neurochemical phenotype could be established irrespective of a putative structural phenotype. Cortical thickness of anatomically defined visual areas was estimated, and a voxel-based morphometry approach was used to assess occipital volumetric changes in ADOA. Neurochemical measurements were focused on γ-aminobutyric acid (GABA) and glutamate, as indicators of the local excitatory/inhibitory balance.

resultsWe found evidence for reduced visual cortical GABA and preserved glutamate concentrations in the absence of cortical or subcortical atrophy. These changes in GABA levels were explained by neither structural nor functional measures of visual loss, suggesting a developmental origin.

conclusionsThese results suggest that mitochondrial disorders that were previously believed to only affect retinal function may also affect cortical physiology, especially the GABAergic system, suggesting reduced brain inhibition vs. excitation. This GABA phenotype, independent of sensory loss or cortical atrophy and in the presence of preserved glutamate levels, suggests a neurochemical developmental change at the cortical level, leading to a pathophysiological excitation/inhibition imbalance.

Indexed as

AdultFemalegamma-Aminobutyric AcidHumansImaging, Three-DimensionalMagnetic Resonance ImagingMaleMitochondriaMitochondrial DiseasesNerve FibersOptic Atrophy, Autosomal DominantRetinal Ganglion CellsTomography, Optical CoherenceVisual AcuityVisual Cortexgamma-Aminobutyric AcidAutosomal dominant optic neuropathyGABAGlutamateNeurotransmissionRetinal ganglion cell

Identifiers

PMID30324419
PMCPMC6224020
OpenAlexW2896488659

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.